05). Conclusion: EPA improves the urinary protein in association with an increase in the EPA/AA ratio in CKD patients with dyslipidemia. EPA may have renoprotective role by reduction of proteinuria in CKD patients. The mechanisms of reduction of proteinuria by EPA would be clarified in the ongoing study. GULATI SANJEEV, KUMAR KAPIL, GUPTA UMESH, Ulixertinib in vivo KALRA VIKRAM, TIWARI S C Fortis Institute of Renal Sciences Introduction: Interstitial fibrosis &

tubular atrophy is the leading cause of graft loss in kidney transplant patient. Proliferation signal inhibitors may help in reducing calcineurin inhibitor exposure without increasing acute rejection episodes. Current study evaluated efficacy of conversion from mycophenolate to everolimus with CNI minimization in patients with biopsy proven

IFTA and deteriorating renal function. Methods: Prospective single center trial, study cohort selected from 200 live related renal transplant recipients in followup. All had received basiliximab induction and triple drug immunosupression (tacrolimus, MMF/EC-MFS, steroids). Inclusion criteria: biopsy proven IFTA, absence of significance proteinuria (<400 mg/24 hour), progressive graft dysfunction (decline of GFR > 15% see more over 1 month), eGFR > 40 ml/min/1.73 m2. All underwent conversion from mycophenolate to everolimus with CNI minimization. Results: The study group composed of 22 patients (M : F = 19:3), mean age 37 years (range 24–58). Conversion done at 24 months PRKACG (IQR: 8.5–24.5) post-transplantation and median follow-up is 22 (IQR: 5–9) months. The tacrolimus trough levels decreased from 5.1 ± 1.6 ng/ml to 3.6 ± 1.1 ng/ml (p = 0.03). The everolimus levels achieved were 6.68 ± 2.4 ng/ml and 5.7 ± 1.4 ng/ml at 1 and 3 months. The eGFR that had declined from best stable values of 59.3 ± 11.9 ml/min to 48.2 ± 9.5 ml/min at conversion stabilized and improved to 50.7 ± 11, 53.3 ± 13.1, 54.9 ± 13.9 and 57.1 ± 10.1 ml/min at 1, 3, 6 and 12 months post conversion respectively (p = 0.028 at 3 months). There were no episodes of rejection, 2 patients was withdrawn at 3 months & 24 months due to proteinuria. Conclusion: Conversion from mycophenolate to everolimus

with CNI minimization resulted in stabilization of renal function. OJIMA SAKI, IO HIROAKI, WAKABAYASHI KEIICHI, KANDA REO, YANAGAWA HIROYUKI, AOKI TATSUYA, NAKATA JUNICHIRO, YAMADA KAORI, NOHARA NAO, SHIMIZU YOSHIO, HAMADA CHIEKO, HORIKOSHI SATOSHI, TOMINO YASUHIKO Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine Introduction: Previous study reported that dialysis patients are easy to occur carnitine deficiency. Thus, they have shown the weakness of the skeletal muscle, cardiomyopathy, heart failure and renal anemia. In the randomized controlled trial of L-carnitine in dialysis patients who had dilated cardiomyopathy, the survival rate of the carnitine administrated group was significantly better than the controled group for 3 years (Rizos I.